MA51996A - Anticorps à domaine unique se liant à la neurotoxine tétanique - Google Patents

Anticorps à domaine unique se liant à la neurotoxine tétanique

Info

Publication number
MA51996A
MA51996A MA051996A MA51996A MA51996A MA 51996 A MA51996 A MA 51996A MA 051996 A MA051996 A MA 051996A MA 51996 A MA51996 A MA 51996A MA 51996 A MA51996 A MA 51996A
Authority
MA
Morocco
Prior art keywords
domain antibodies
tetanus neurotoxin
neurotoxin
tetanus
antibodies
Prior art date
Application number
MA051996A
Other languages
English (en)
Inventor
Smit Abraham Johannes De
Michaël Marie Harmsen
Original Assignee
Smivet B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smivet B V filed Critical Smivet B V
Publication of MA51996A publication Critical patent/MA51996A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
MA051996A 2018-03-13 2019-03-13 Anticorps à domaine unique se liant à la neurotoxine tétanique MA51996A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18161521 2018-03-13

Publications (1)

Publication Number Publication Date
MA51996A true MA51996A (fr) 2021-01-20

Family

ID=61691657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051996A MA51996A (fr) 2018-03-13 2019-03-13 Anticorps à domaine unique se liant à la neurotoxine tétanique

Country Status (9)

Country Link
US (1) US20220275066A1 (fr)
EP (1) EP3765495A1 (fr)
JP (2) JP2021516682A (fr)
CN (1) CN112135840B (fr)
AU (1) AU2019233603A1 (fr)
BR (1) BR112020018563A2 (fr)
MA (1) MA51996A (fr)
MX (1) MX2020009507A (fr)
WO (1) WO2019175250A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
EP0698097B1 (fr) 1993-04-29 2001-08-16 Unilever N.V. Production d'anticorps ou de fragments fonctionnalises d'anticorps, derives des immunoglobulines a chaine lourde de camelidae
EP0739981A1 (fr) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
AUPS022802A0 (en) * 2002-01-31 2002-02-21 Macfarlane Burnet Institute For Medical Research And Public Health Limited, The Anti-viral compounds
EP1634076A2 (fr) 2003-06-10 2006-03-15 CatchMabs B.V. Peptides de liaison: méthodes pour leur génération et usage
JP5184374B2 (ja) * 2006-01-25 2013-04-17 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 対立遺伝子排除
EP2650311A3 (fr) * 2007-11-27 2014-06-04 Ablynx N.V. Séquences d'acides aminés dirigées contre des cytokines hétérodimériques et/ou leurs récepteurs et polypeptides les comprenant
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
IN2012DN00733A (fr) * 2009-07-02 2015-06-19 Merz Pharma Gmbh & Co Kgaa
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2012088461A2 (fr) 2010-12-23 2012-06-28 Biogen Idec Inc. Peptides coupleurs et polypeptides les comportant
RU2646110C2 (ru) * 2011-11-09 2018-03-01 Мерц Фарма Гмбх Унд Ко. Кгаа Нейротоксины, проявляющие укороченную биологическую активность
WO2013110531A1 (fr) * 2012-01-23 2013-08-01 Ablynx Nv Séquences dirigées contre le facteur de croissance des hépatocytes (hgf) et polypeptides les comprenant pour le traitement de cancers et/ou de tumeurs
CA2980642C (fr) * 2015-03-25 2022-09-20 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Complexe cytotoxique anti-cd89
IL293719B2 (en) * 2015-05-21 2023-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use

Also Published As

Publication number Publication date
EP3765495A1 (fr) 2021-01-20
US20220275066A1 (en) 2022-09-01
CN112135840B (zh) 2024-01-23
JP2024023268A (ja) 2024-02-21
BR112020018563A2 (pt) 2020-12-29
MX2020009507A (es) 2020-10-22
JP2021516682A (ja) 2021-07-08
WO2019175250A1 (fr) 2019-09-19
CN112135840A (zh) 2020-12-25
AU2019233603A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MA51734A (fr) Anticorps se liant à gprc5d
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA53434A (fr) Anticorps anti-tigit
MA42380A (fr) Anticorps se liant à tau
MA52884A (fr) Anticorps anti-il-11
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA47268A (fr) Anticorps anti-gpc3
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA44381A (fr) Format d'anticorps hétérodimères multispécifiques
MA54514A (fr) Anticorps se liant à cd3
MA42626A (fr) Nouveaux anticorps anti-pd-1
MA42377A (fr) Anticorps se liant à tau
MA43660A (fr) Anticorps anti-facteur xi de coagulation
MA50352A (fr) Anticorps multispécifiques
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA43738A (fr) Anticorps anti-tnfalpha et leurs fragments fonctionnels
MA52152A (fr) Anticorps
MA45234A (fr) Anticorps anti-facteur xi de coagulation
MA42843A (fr) Anticorps anti-cd115
MA51134A (fr) Anticorps anti-alpha-synucléine
MA49250A (fr) Nouveaux anticorps anti-cd3
MA53322A (fr) Anticorps procoagulants améliorés